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7Research articleReduced trabecular bone mineral density and 
cortical thickness accompanied by increased outer 
bone circumference in metacarpal bone of 
rheumatoid arthritis patients: a cross-sectional 
study
Daniel Aeberli*†1, Prisca Eser†1, Harald Bonel2, Jolanda Widmer1, Gion Caliezi1, Pierre-Alain Varisco1, Burkhard Möller1 
and Peter M Villiger1
Abstract
Introduction: The objective of this study was to assess three-dimensional bone geometry and density at the epiphysis 
and shaft of the third meta-carpal bone of rheumatoid arthritis (RA) patients in comparison to healthy controls with the 
novel method of peripheral quantitative computed tomography (pQCT).
Methods: PQCT scans were performed in 50 female RA patients and 100 healthy female controls at the distal 
epiphyses and shafts of the third metacarpal bone, the radius and the tibia. Reproducibility was determined by 
coefficient of varia-tion. Bone densitometric and geometric parameters were compared between the two groups and 
correlated to disease characteristics.
Results: Reproducibility of different pQCT parameters was between 0.7% and 2.5%. RA patients had 12% to 19% lower 
trabecular bone mineral density (BMD) (P ≤ 0.001) at the distal epiphyses of radius, tibia and metacarpal bone. At the 
shafts of these bones RA patients had 7% to 16% thinner cortices (P ≤ 0.03). Total cross-sectional area (CSA) at the 
metacarpal bone shaft of pa-tients was larger (between 5% and 7%, P < 0.02), and relative cortical area was reduced by 
13%. Erosiveness by Ratingen score correlated negatively with tra-becular and total BMD at the epiphyses and shaft 
cortical thickness of all measured bones (P < 0.04).
Conclusions: Reduced trabecular BMD and thinner cortices at peripheral bones, and a greater bone shaft diameter at 
the metacarpal bone suggest RA spe-cific bone alterations. The proposed pQCT protocol is reliable and allows 
measuring juxta-articular trabecular BMD and shaft geometry at the metacarpal bone.
Introduction
Juxta-articular bone loss is one of the earliest radio-
graphic findings of active rheuma-toid arthritis (RA)
[1,2]. Recently, loss of bone mass at the metacarpal shafts
meas-ured on plain radiographs of the hand has been
found to be predictive of subsequent joint damage in
patients with active rheumatoid arthritis [1,3]. So far,
reduced bone mass at the metacarpal bone shaft in RA
has been documented in a number of stud-ies using Digi-
tal X-ray Radiogrammetry (DXR) [1,3-5] or at the hand
by Dual X-ray Absorptiometry (DXA) [3,6-8]. Trabecular
bone loss in RA patients, however, has on-ly been studied
at the iliac crest [9] and at the distal radius [10-12], where
it was found to be lower in RA patients than in controls
[9,11].
Peripheral Quantitative Computed Tomography
(pQCT) is a three-dimensional measuring technique that
allows the assessment of cross-sectional bone geometry
and volumetric bone mineral density (vBMD). In contrast
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allows the determination of bone geometry of bone
cross-section independent of bone size. To date, no study
has examined vBMD and cross-sectional bone geometry
of the metacarpal bones in RA. We have recently used
pQCT for measuring metacarpal bone in patients with
diffuse idiopathic skeletal hy-perostosis (DISH) patients
[13]. Interestingly, juvenile idiopathic arthritis measure-
ments of bone mineral density and geometry by pQCT
have shown that articular and periarticular inflammation
is associated with bone loss and changes in bone geome-
try, in particular reduced cortical thickness and increased
bone cross-sectional area [14-17].
The aim of the present study was to assess vBMD and
bone geometry of metacarpal bone, radius and tibia in
patients with established RA by pQCT and to compare
these peripheral bone parameters to those of healthy con-
trols.
Materials and methods
We conducted a prospective observational study compar-
ing female RA patients to a control group. The study pro-
tocol was approved by the Ethics Committee of the Can-
ton of Bern.
Subjects
Consecutive female RA patients, fulfilling the American
College of Rheumatology cri-teria [18], seen in the
Department of Rheumatology and Clinical Immunology,
Insel-spital Bern, were included. For the control group,
we recruited healthy female volun-teers by locally distrib-
uted flyers and advertisement on the hospital internal
web. In-clusion criteria were for both groups age 20 to 90
years. Exclusion criteria for both groups were bone meta-
bolic diseases, hyper-/hypoparathyroidism, hy-per/hypo-
thyreoidism, chronic renal insufficiency, cancer,
pregnancy, lactation and drug addiction on the basis of
medical history and questionnaires for osteoporosis risk
factors. For the control group, established osteoporosis
and previous or present bisphosphonate therapy were
also exclusion criteria. All patients and volunteers gave
written informed consent.
Assessment of disease characteristics
Erosiveness was assessed by total Ratingen score [19] for
the non-dominant hand by a study-independent radiolo-
gist and a rheumatologist. From medical records, most
recently determined Rheumatoid Factor (RF) and anti-
Cyclic Citrullinated Peptide an-tibody (anti-CCP), dis-
ease duration, modified disease activity score
(DAS)including 28 joints [20], therapy with regard to
anti-tumor necrosis factor (anti-TNF), bisphos-phonate
and glucocorticoids were extracted.
Bone measurements
Measurements were performed with a Stratec XCT 3000
scanner (Stratec Medizin-technik, Pforzheim, Germany).
This pQCT apparatus measures attenuation of x-rays
which are linearly transformed into hydroxylapatit (HA)
densities. Unlike some other pQCT scanners, the Stratec
XCT 3000 is calibrated with respect to water which is set
at 60 mg HA, so that fat results in 0 mg HA [21]. HA
equivalent densities are auto-matically calculated from
the attenuation coefficients by employing the manufac-
turer's phantom which itself is calibrated with respect to
the European Forearm Phan-tom (Erlangen, Germany)
[21]. PQCT measurements of the radius and the metacar-
pal bone were performed on the non-dominant side and
at the tibia on the opposite leg.
Metacarpal measurements
Length of metacarpal bone III of the non-dominant hand
was palpated and measured from base to head by mea-
suring tape to the nearest 5 mm. The subjects were seated
in a chair side on to the gantry and had their arm and
hand resting on a custom made flat wooden holder. The
arm was abducted to 90 degrees with the elbow, wrist and
fingers extended and palm facing down. Several Velcro
straps centered the middle finger and arm on the slightly
padded wooden holder and held the arm securely in
place. The Velcro strap around the middle finger attached
along the middle axis of the wooden holder ensured that
the axis of the third metacarpal bone was in line with the
central axis of the forearm and perpendicular to the gan-
try. A scout view was per-formed of the head of ossa
metacarpalia III (Figure 1a) and the reference line was
placed at the distal end of the bone (Figure 1b, c). Scans
were performed at 4%, 30% and 50% of the total bone
length measured from the distal bone end. Slice thickness
was 2.2 mm, voxel size was set at 0.3 mm edge length, and
scanning speed was set at 15 mm/s. Reference line place-
ment and typical pQCT images of metacarpal measure-
ments of a control subject and an RA patient are
illustrated in Figure 1b, c.
Radius and tibia measurements
Radius bone length was set equal to ulnar length, which
was measured to the near-est 5 mm with a measuring
tape by palpation from the olecranon to the ulnar styloid.
Tibia length was determined from the medial knee joint
cleft to the end of the medial malleolus. A scout view of
the distal end of the tibia/radius was performed and the
automated detection algorithm provided by the manufac-
turer was used to place the reference line at the distal
bone end. Scans were performed according to manufac-
turer's recommendations at 4% and 66% of the bone's
total length measured from the reference line. Slice thick-
ness was 2.2 mm, and voxel size was set at 0.5 mm with a
scanning speed of 20 mm/s. The manufacturer's software
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Figure 1 Placement of scout view (a) and typical scout view with reference line placement and the 3 metacarpal scans in a healthy refer-
ence par-ticipant (b) and RA patient (c). The third metacarpal bone is indicated with a white arrow.
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many) was used for analysis.
Measuring parameters
Epiphyseal scan (4%): The periosteal surface of each
bone's epiphysis was found by a contour algorithm based
on thresholding at 200 mg/cm3 (metacar-pals) and 180
mg/cm3 (radius and tibia, contour mode 1 and peel mode
1 of the software). Bone mineral content (BMC) per cm
slice thickness, total cross-sectional area (CSA) and total
volumetric bone mineral density (BMD) were de-ter-
mined. Concentric pixel layers were then peeled off from
the bone's perimeter until a central area covering 50%
(metacarpals) or 45% (radius and tibia) of the total bone
CSA was left. Trabecular BMD was determined from this
central area.
Diaphyseal scans (30% and 50% for metacarpals, 66%
for radius and tibia): The threshold for the periosteal sur-
face was set at 280 mg/cm3 and from this BMC and total
CSA were calculated. Cortical bone was selected by
thresholding at 710 mg/cm3 (contour mode 1 and peel
mode 1), and from this, corti-cal CSA and cortical BMD
were calculated. Cortical thickness was calculated based
on the assumption that the bone shaft be cylindrical from
total CSA, which included the bone marrow, and cortical
CSA of the diaphyseal scans. At the 50% scan of the meta-
carpal bone the relative cortical area was calculated as
cortical CSA/total CSA. This relative cortical area is pro-
portional to the metacarpal index commonly meas-ured
on standard x-rays or digitised radiography. Muscle CSA
was determined by se-lecting the area with a lower
threshold of 40 mg/cm3 and an upper threshold of 280
mg/cm3 HA density after smoothing the image (con-tour
mode 3 and peel mode 1, and contour mode 1 and peel
mode 2 for subtracting the bone area).
Precision of metacarpal bone measurements
Nine subjects of the control group volunteered to have a
total of four measurements of metacarpal bone III of the
same hand within a maximal time span of three weeks (or
three months in one subject). The two operators who
performed the measure-ments of this study completed
two measurements each in each of the nine subjects. If
repeat measurements were performed on the same day,
subjects were completely repositioned between the two
scans.
Data analysis
To determine reproducibility of the new protocol coeffi-
cients of variation (CV) for met-acarpal bone measure-
ments were calculated as root-mean-square (RMS)
averages of standard deviations [22] including all four
measurements of all nine subjects. Nine-ty-five percent
confidence intervals (CI) of the CVs were calculated by
bootstrapping (n = 2,000 simulations). Because some of
the bone parameters were not normally distributed,
Mann-Whitney tests were performed between the refer-
ence group and the RA group with regard to age, height,
weight, and muscle CSA of the forearm and lower leg.
Mann-Whitney tests were also performed for all bone
parameters of the third metacarpal bone, the radius and
the tibia. For easier interpretation of the results, means
and standard deviations of all parameters for each group
as well as relative differences between groups were calcu-
lated. Furthermore, ANCOVAs with muscle CSA as
covariate (forearm muscle CSA for radial and metacarpal
bone parameters and lower leg muscle CSA for tibial
bone parameters) were performed for all bone parame-
ters to adjust for the significant between-group differ-
ences in lower leg mus-cle CSA and trend for forearm
muscle CSA. In the RA group Spearman correlation coef-
ficients were calculated between trabecular and total
BMD, as well as cortical thickness and total Ratingen
score. Statistical analyses were performed with SPSS ver-
sion 17.0 (SPSS Inc., Zurich, Switzerland), and statistical
significance was set at an alpha of 0.05.
Results
Subject parameters
A total of 50 RA patients and 100 control subjects ful-
filled the selection criteria and were recruited for the
present study. Two patients had metal implants at the
non-dominant radius, in these patients the dominant
radius was measured. Subject char-acteristics are pre-
sented in Table 1. The two groups were comparable with
regard to age and weight. However, RA patients had a 9%
smaller muscle CSA at the lower leg (P = 0.01) and mus-
cle CSA at the lower arm of the RA group tended to be
5% smaller (P = 0.10). The RA patients' height tended to
be 10% small-er (P = 0.09).
Table 1: Subject anthropometric data (mean ± standard deviation)
Parameter RA patients Reference group P-value
Number of 
subjects
50 100
Age (y) 55.3 ± 11.4 54.1 ± 12.9 0.481
Height (cm) 163.4 ± 6.2 165.0 ± 5.7 0.092
Weight (kg) 67.0 ± 13.8 63.6 ± 9.8 0.183
Forearm muscle 
CSA (cm2)
24.0 ± 4.0 25.3 ± 3.5 0.102
Lower leg muscle 
CSA (cm2)
58.1 ± 11.3 63.7 ± 10.6 0.014
P-values are indicated for two-sided Mann-Whitney-tests (significant 
P-values in bold). CSA stands for cross-sectional area.
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Mean (SD) disease duration was 11.4 (9.5) yrs (median
8.1 yrs) and mean disease activity (DAS28) 4.2 (1.1).
Sixty-nine percent were classified erosive, 67% were posi-
tive for RF and 85% for anti-CCP. Anti-TNF therapy was
previously given to 62% (mean duration was 14.4
months), and bisphosphonates to 35%. Seventy-two per-
cent had been on glucocorticoid therapy during the year
previous to pQCT measure-ment.
Precision of metacarpal bone measurements
Coefficients of variation (CV) with 95% CI reflecting the
measuring errors for the measured bone parameters at
the third metacarpal bone are shown in Table 2. CVs were
smaller than or equal to 2.5% for all measured parame-
ters. Upper limits of 95% CI were between 0.99% and
2.99%.
Bone characteristics in RA patients
Trabecular BMD at the distal epiphyses of metacarpals,
radius and tibia were 13% to 19% lower in the RA group
compared to the control group (P ≤ 0.001, Table 3). Total
BMD was 10% lower at the distal tibia and 9% lower at the
distal third meta-carpal bone in the RA group (P ≤ 0.001).
Cortical thickness was 7% to 16% thinner at all three
shafts (P < 0.03). Total CSA was between 5% and 7%
greater at the 30% and 50% site of the metacarpal shaft in
the RA groups (P < 0.02). Cortical BMD was smaller in
the RA group (except for the tibial shaft), a finding most
probably caused by partial volume effect [23] due to the
thinner cortices rather than real differences. The relative
cortical area was 12.5% smaller in the RA patients (P =
0.001). Differences in standard deviations of metacarpal
bone parameters between the RA and control group are
shown in Figure 2.
Results of the ANCOVAs adjusting for muscle CSA are
shown in Table 4. Differences in intercepts of the two
groups (assessed at mean muscle CSA) remained signifi-
cant for trabecular BMD and cortical thickness of all
three bones (except cortical thickness of the tibia), and
total CSA of the metacarpal bone was even more signifi-
cantly great-er in the RA group after adjustment for mus-
cle CSA. In addition, many of the per-formed ANCOVAs
showed a significant interaction between group and mus-
cle CSA (difference in slopes on Table 4), meaning that
the slope of the linear relationship be-tween muscle and
bone parameter was different in the two groups. All bone
parame-ters of the RA group, except cortical BMD, were
associated with muscle CSA (slope of RA group in Table
4).
Relationship between erosive status and bone parameters
Total Ratingen score correlated negatively with total and
trabecular BMD at all three measured bone sites (r
between -0.36 and - 0.48, P ≤ 0.011), and with corti-cal
thickness at all three measured shafts (radius and tibia: r
between - 0.31 and - 0.38, P ≤ 0.04, metacarpal shaft: r
between - 0.42 and to - 0.51, P ≤ 0.003).
Discussion
The detailed three-dimensional assessment of peripheral
bone vBMD and geometry of the present study shows a
systemically lower trabecular BMD and thinner cortices
in RA patients and a localised greater outer bone shaft
circumference at the meta-carpal bone.
Table 2: Results of pQCT reproducibility measurements (four measurements in each of nine subjects) of the third metacarpal bone
Scan location Bone parameter Overall mean SD CV (%) 95% CI of CV (%)
Distal epiphysis (4%) BMC (mg/mm) 46.4 0.76 1.64 1.18 to 2.14
Total CSA (mm2) 124.1 2.82 2.27 1.72 to 2.77
Total BMD (mg/cm3) 373.6 3.69 0.99 0.77 to 1.24
Trabecular BMD [mg/cm3] 331.0 8.10 2.45 1.96 to 2.99
Shaft (30%) BMC (mg/mm) 52.4 0.71 1.35 0.98 to 1.70
Total CSA (mm2) 75.7 1.42 1.87 1.32 to 2.26
Cortical CSA (mm2) 38.1 0.59 1.55 1.13 to 2.10
Cortical BMD (mg/cm3) 1,166.38 10.29 0.88 0.62 to 1.12
Shaft (50%) BMC (mg/mm) 52.8 0.44 0.84 0.62 to 1.11
Total CSA (mm2) 58.8 0.86 1.46 1.01 to 1.92
Cortical CSA (mm2) 39.3 0.40 1.02 0.67 to 1.33
Cortical BMD (mg/cm3) 1,205.8 8.51 0.71 0.41 to 0.99
Indicated are overall mean value, standard deviation (SD), Coefficient of variation (CV) and 95% confidence interval (CI) of the CV. BMC stands for 
bone mineral content per mm of slice thickness, CSA for cross-sectional area and BMD for volumetric bone mineral density.
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Table 3: Bone parameters at the radius, tibia, and third metacarpal bone in RA patients and controls (means ± sd), P-values of two-sided 
Mann-Whitney tests (significant values are in bold), and difference between mean values of RA and control group
Group RA (n = 50) Ref (n = 100) Mann-Whitney
test P-value
Relative 
difference [%]
Bone Site Parameter Mean SD Mean SD
Radius 4% BMC (g/cm) 1.03 0.23 1.09 0.17 0.087 -5.5
Total CSA (mm2) 339.3 55.3 338.4 48.2 0.599 0.3
Total BMD (mg/cm3) 305.3 58.2 325.5 53.1 0.076 -6.2
Trab. BMD (mg/cm3) 151.6 47.3 186.1 38.4 0.000 -18.5
66% BMC (g/cm) 0.89 0.21 0.98 0.16 0.009 -9.2
Total CSA (mm2) 139.4 26.1 132.6 20.7 0.110 5.1
Cort. CSA (mm2) 63.3 19.6 71.8 13.3 0.017 -11.8
Cort. BMD (mg/cm3) 1,094.0 78.7 1137.6 57.3 0.000 -3.8
Cort. Thickness (mm) 1.80 0.59 2.14 0.45 0.001 -15.9
Tibia 4% BMC (g/cm) 2.76 0.60 3.02 0.43 0.002 -8.6
Total CSA (mm2) 1,087.6 161.2 1071.7 126.9 0.251 1.5
Total BMD (mg/cm3) 255.0 47.7 284.6 43.7 0.000 -10.4
Trab. BMD (mg/cm3) 192.5 43.5 222.9 37.3 0.000 -13.6
66% BMC (g/cm) 3.54 0.54 3.72 0.43 0.085 -4.8
Total CSA (mm2) 549.9 81.4 548.3 67.6 0.956 0.3
Cort. CSA [mm2) 266.4 43.9 282.6 33.4 0.048 -5.7
Cort. BMD (mg/cm3) 1,117.0 54.8 1130.6 36.6 0.152 -1.2
Cort. Thickness (mm) 3.78 0.65 4.05 0.52 0.029 -6.7
MCP3 4% BMC (mg/mm) 40.48 9.96 43.70 7.18 0.031 -7.4
Total CSA (mm2) 124.8 19.6 124.2 13.0 0.751 0.5
Total BMD (mg/cm3) 321.6 66.0 351.8 44.4 0.001 -8.6
Trab. BMD (mg/cm3) 266.0 80.5 303.2 44.9 0.001 -12.3
30% BMC (mg/mm) 43.68 11.34 47.07 6.16 0.130 -7.2
Total CSA (mm2) 76.10 13.60 71.26 11.52 0.015 6.8
Cort. CSA (mm2) 31.59 8.49 34.66 4.22 0.088 -8.9
Cort. BMD (mg/cm3) 1,100.1 87.5 1146.2 57.7 0.005 -4.0
Cort. Thickness (mm) 1.19 0.36 1.38 0.23 0.005 -13.8
50% BMC (mg/mm) 44.97 11.39 48.25 6.22 0.102 -6.8
Total CSA (mm2) 59.69 8.15 56.66 6.13 0.019 5.3
Cort. CSA (mm2) 33.04 8.56 36.06 4.70 0.043 - 8.4
Cort. BMD (mg/cm3) 1,153.0 76.5 1,189.9 44.7 0.008 -3.1
Cort. Thickness (mm) 1.48 0.45 1.71 0.28 0.001 -13.5
relative cortical area 0.56 0.14 0.64 0.08 0.001 -12.5
P-values are rounded to three decimal places, values of 0.000 are equivalent to P < 0.0005. BMC stands for bone mineral content per mm of slice 
thickness, CSA for cross-sectional area, BMD for volumetric bone mineral density, trab for trabecular and cort for cortical.
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radius and the tibia was lower in RA patients than con-
trols. This was in accordance with earlier studies using
DXA where the RA population was found to have lower
total BMD at the distal metacarpal bone [7], at the distal
radius [10,12,24], and the hip [11,25,26].
The metacarpal bone shafts of our RA patients were
thinner and had a greater outer bone diameter (Figure 2).
These results are in good agreement with a recent pub-
lica-tion on patients with polyarticular juvenile idiopathic
arthritis [14]. The between-group deficits in trabecular
BMD could not be accounted for by adjustment to muscle
cross-sectional area (CSA), indicating that the bone defi-
cit in RA patients was greater than what would be
expected as a result of their atrophied muscles. The same
was true for cortical thickness of the radius and metacar-
pal shafts. However, at the tibia shaft, differences in corti-
cal thickness disappeared after adjusting for muscle CSA
(Table 4). It should be noted that the slope of the muscle
CSA to cortical thickness relation-ship differed, indicat-
ing that the thinning of the tibial cortex with decreasing
muscle CSA was amplified in the RA group. In addition,
the greater outer metacarpal diame-ter in our RA
patients stands in contrast to the smaller muscle CSA.
This may indi-cate that while part of the deficit in trabec-
ular BMD and cortical thickness may have been caused
by muscle atrophy, other disease related processes further
reduced jux-ta-articular trabecular BMD and altered
shaft geometry. Two pathomechanisms for decreased
cortical thickness and increased outer circumference of
the shaft are cur-rently discussed: First, bony apposition
is seen as a compensatory mechanism to counterbalance
inflammation to induced cortical thinning [14]. Second,
periosteal bone formation is seen as a repair process in
inflammation-induced increased bone turnover [27,28].
Irrespective of the causality of the greater outer bone
shaft diame-ter, the result is an improved bone resistance
against bending and torsion [29].
We found a significant negative correlation between
erosive score and total and tra-becular BMD as well as
cortical shaft thickness at all measured bones. This is in
ac-cordance with the relationship between development
of erosions at the wrist and fin-gers and the loss of areal
BMD at the metacarpal bone measured by digital x-ray
ra-diogrammetry [1,4,30]. Significantly lower baseline
areal BMD at the hip [31,32] and spine [33] was found in
early RA patients with erosive development, pointing to a
general bone loss as consequence of a systemic inflamma-
tory process. Our data of the radius and tibia support the
notion of a systemic inflammatory process. Our more
detailed analysis of vBMD and bone geometry showed
lower trabecular vBMD at the radius and tibia and a thin-
ner shaft cortical thickness at the radius independent of
muscle atrophy, suggesting that systemic inflammatory
processes may be involved. However, the greater shaft
outer diameter was seen only at the metacarpal bone
shaft suggesting RA-specific alterations at the metacarpal
bone.
The presented data document a good performance of a
newly developed protocol for measuring volumetric
Figure 2 Effect size of bone parameters at the metacarpal bone between RA patients and healthy controls. The error bars indicate 95% con-
fidence interval of the between group differences in mean SD of both groups.
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Bone Site Parameter Difference between 
intercepts (P-value)
Difference between 
slopes (P-value)
Slope of RA group 
(P-value)
Radius 4% BMC (g/cm) 0.01 (0.610)  - 0.01 (0.045) 0.04 (0.000)
Total CSA (mm2) - 10.64 (0.190) - 2.10 (0.319) 7.62 (0.000)
Total BMD (mg/cm3) 15.94 (0.099) - 1.76 (0.483) 4.16 (0.035)
Trab. BMD (mg/cm3) 28.50 (0.000) - 3.61 (0.052) 5.29 (0.000)
66% BMC (g/cm) 0.05 (0.050) - 0.01 (0.154) 0.03 (0.000)
Total CSA (mm2) - 10.82 (0.003) - 1.54 (0.108) 3.84 (0.000)
Cort. CSA (mm2) 5.57 (0.023) - 0.69 (0.281) 2.70 (0.000)
Cort. BMD (mg/cm3) 42.58 (0.000) 0.55 (0.869) 1.07 (0.686)
Cort. Thickness (mm) 0.29 (0.001) - 0.01 (0.657) 0.05 (0.004)
Tibia 4% BMC (g/cm) 0.08 (0.267) - 0.02 (0.003) 0.04 (0.000)
Total CSA (mm2) - 53.01 (0.031) - 5.18 (0.017) 7.80 (0.000)
Total BMD (mg/cm3) 22.13 (0.008) - 0.52 (0.471) 1.66 (0.005)
Trab. BMD (mg/cm3) 21.71 (0.003) - 1.68 (0.008) 2.15 (0.000)
66% BMC (g/cm) 0.02 (0.742) - 0.01 (0.024) 0.04 (0.000)
Total CSA (mm2) - 17.41 (0.178) - 0.91 (0.424) 3.13 (0.001)
Cort. CSA (mm2) 2.75 (0.619) - 1.38 (0.005) 2.98 (0.000)
Cort. BMD (mg/cm3) 11.42 (0.169) 0.05 (0.944) 0.38 (0.518)
Cort. Thickness (mm) 1.14 (0.171) - 0.02 (0.038) 0.03 (0.000)
MCP3 4% BMC (mg/cm) 1.40 (0.266) - 0.35 (0.287) 1.41 (0.000)
Total CSA (mm2) - 2.74 (0.299) - 0.42 (0.543) 1.71 (0.002)
Total BMD (mg/cm3) 21.60 (0.014) - 3.36 (0.138) 7.52 (0.000)
Trab. BMD (mg/cm3) 25.98 (0.008) - 4.28 (0.092) 8.64 (0.000)
30% BMC (mg/cm) 1.67 (0.194) - 0.60 (0.074) 1.47 (0.000)
Total CSA (mm2) - 7.33 (0.000) - 0.86 (0.092) 2.08 (0.000)
Cort. CSA (mm2) 1.76 (0.056) - 0.49 (0.039) 1.13 (0.000)
Cort. BMD (mg/cm3) 43.98 (0.001) - 1.39 (0.667) 2.61 (0.300)
Cort. Thickness (mm) 0.16 (0.001) - 0.01 (0.419) 0.03 (0.014)
50% BMC (mg/cm) 1.45 (0.229) - 0.43 (0.168) 1.58 (0.000)
Total CSA (mm2) - 4.40 (0.000) - 0.44 (0.113) 1.18 (0.000)
Cort. CSA (mm2) 1.60 (0.073) - 0.38 (0.099) 1.25 (0.000)
Cort. BMD (mg/cm3) 32.25 (0.002) - 1.97 (0.452) 4.51 (0.029)
Cort. Thickness (mm) 0.18 (0.002) - 0.01 (0.588) 0.04 (0.000)
relative cortical area 0.07 (0.000) - 0.00 (0.617) 0.01 (0.017)
For bone parameters of the radius and metacarpal bone muscle CSA of the forearm (cm2) was used, and for the tibia muscle CSA at the lower leg 
(cm2) was used. Bold P-values indicate significant coefficients. P-values are rounded to three decimal places, values of 0.000 are equivalent to P 
< 0.0005. BMC stands for bone mineral content per mm of slice thickness, BMD for volumetric bone mineral density, trab for trabecular and cort 
for cortical.
BMD and bone geometry by pQCT at the third metacar-
pal bone. Reproducibility was similar to previous studies
measuring metacarpal areal BMD in RA patients by DXA
[7,34] and in studies using pQCT (XCT 3000) at the ra-
dius [35], tibia [35-37], femur [35-37] and humerus [35].
CVs at the metacarpal mid-shaft (50% scan) of our proto-
col ranged from 0.7% to 1.5%. This is higher than the CV
of 0.14% to 0.3% reported for digital X-ray radiogram-
metry [38], and most proba-bly due to the higher suscep-
tibility to malpositioning. We have also performed inter-
Aeberli et al. Arthritis Research & Therapy 2010, 12:R119
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(ICC) and have found all ICCs > 0.85. Indeed, most ICCs
were > 0.99, and they were similar between and within
the two operators, indicating that the measuring protocol
was not operator-sensitive.
A limitation of the present study is the large number of
conducted statistical tests. Therefore, even P-values well
below 0.05 should be interpreted carefully. However, the
main results of this study, namely the between-group dif-
ferences in tra-becular BMD and cortical thickness of all
measured bones had P-values of ≤ 0.005 (except for the
tibia shaft cortical thickness with a P-value of 0.03), and
total CSA of the metacarpal bone had a P-value of < 0.02.
Further, RA patients were on various medications that
influence bone metabolism (biologicals, glucocorticoids,
bisphosphonates). However, the aim of the present study
was to compare a cohort of RA patients treated according
to current common practice with healthy controls. Our
results highlight that despite the bone protective effects
of bio-logicals and bisphosphonates, trabecular BMD and
cortical thickness were reduced at all measured skeletal
sites in RA patients. While there were no clear associa-
tions between bone parameters and use of biological or
glucocorticoids, patients on bisphosphonates had signifi-
cantly lower trabecular BMD at all measured epiphyses
(with diagnosis of osteoporosis being the treatment indi-
cation)(data not shown).
Conclusions
In RA patients, trabecular BMD at the distal epiphyses of
metacarpals, radius and tib-ia was lower compared to
controls, and cortical thickness was thinner at the shafts.
Furthermore, the outer bone diameter at the metacarpal
shaft was larger in RA pa-tients compared to controls.
This suggests inflammation- and probably disease- spe-
cific mechanisms being operative in bone remodelling. It
remains to be shown whether these changes may help to
monitor disease progression and guide treat-ment inten-
sity.
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